Antisoma Reports Positive Results in Cancer Drug Study
Posted on: Thursday, 6 September 2007, 06:14 CDT
Cancer drug developer Antisoma said results from its Phase II trial evaluating its experimental lung cancer drug demonstrated positive survival rates.
The single-arm Phase II trial evaluated a 1800mg/m2 dose of ASA404 in combination with carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer. Median survival was 14.9 months, median time to tumor progression was 5.5 months and the tumor response rate was 37.9%. The addition of ASA404 to chemotherapy was well tolerated, Antisoma said.
These data support the findings from an earlier, randomized Phase II trial in which the addition of ASA404 to chemotherapy produced one of the largest increases in median survival ever reported in advanced lung cancer, according to the company. In that trial, patients who received a 1200mg/m2 dose of ASA404 combined with chemotherapy had a median survival of 14 months whereas patients who received chemotherapy alone had a median survival of 8.8 months.
Antisoma's partner, Novartis, plans to start enrollment of patients into a phase III trial in non-small cell lung cancer in early 2008.
Source: Datamonitor
Related Articles
- ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Data From Satraplatin SPARC Phase 3 Trial in Patients With Hormone-Refractory Prostate Cancer Progressing After Initial Chemotherapy Presented at 44th ASCO Annual Meeting
- NeoPharm Enrolls First Patient in Phase I Trial for Patients With Metastatic Solid Cancer
- OncoGenex Reports Updated Survival Data on OGX-011 in a Second-Line Chemotherapy Trial for Patients With Prostate Cancer
- Oncolytics Completes Patient Enrollment in Phase Ia/Ib Cancer Trial
- HistoRx AQUA(R) Technology Identifies Two Biomarkers Linked to Lung Cancer Survival
- MAP Pharmaceuticals Initiates Phase 2 Clinical Trial in Patients With Migraine
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Hormone Dependent Prostate Cancer
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Colorectal Cancer
 |
 |
User Comments (0)
RSS Feeds